Corynoxeine 产品活性：Corynoxeine, 从 Uncaria rhynchophylla 的钩中分离的，是 PDGF-BB 诱导血管平滑肌细胞 (VSMCs) 增殖过程中的一种有效 ERK1/ERK 2 抑制剂。 产品来源： https://www.medchemexpress.cn/Corynoxeine.html 研究领域：MAPK/ERK Pathway | Stem Cell/Wnt 作用靶点：ERK 来源：植物 | 茜草科 | 钩藤 结构分类：生物碱 | 吲哚类生物碱 In Vitro: Corynoxeine is able to inhibit the PDGF-BB-stimulated proliferation of VSMCs through downregulation of PDGF-BB-induced ERK1/2 activation. Pre-incubation of VSMCs with Corynoxeine significantly inhibits PDGF-BB-induced extracellular signal-regulated kinase 1/2 (ERK1/2) activation, whereas Corynoxeine has no effects on mitogen-activated protein kinase (MAPK/ERK)-activating kinase 1 and 2 (MEK1/2), Akt, or phospholipase C (PLC) γ 1 activation or on PDGF receptor beta (PDGF-Rβ) phosphorylation. Corynoxeine inhibits PDGF-BB-induced ERK1/2 activation, in the same concentration range that inhibits VSMC proliferation and DNA synthesis. Corynoxeine inhibits VSMC numbers in response to PDGF-BB with 50% inhibitory concentrations (IC50) of 13.7 μM. Corynoxeine inhibits DNA synthesis in response to PDGF-BB (24 h) with IC50 of 9.2 μM. Pre-treatment of VSMCs with Corynoxeine (5-50 μM) for 24 h results in significant decreases in cell number without any cytotoxicity; the inhibition percentages are 25.0±12.5, 63.0±27.5 and 88.0±12.5% at 5, 20 and 50 μM, respectively. Corynoxeine also significantly inhibits the 50 ng/mL PDGF-BB-induced DNA synthesis of VSMCs in a concentration-dependent manner without any cytotoxicity; the inhibitions are 32.8±11.0, 51.8±8.0 and 76.9±7.4% at concentrations of 5, 20 and 50 μM, respectively. 相关产品：Natural Product Library Plus | Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | Kinase Inhibitor Library | MAPK Compound Library | Stem Cell Signaling Compound Library | Natural Product Library | Anti-Aging Compound Library | Reprogramming Compound Library | Oxygen Sensing Compound Library | Anti-Cardiovascular Disease Compound Library | Glutamine Metabolism Compound Library | Traditional Chinese Medicine Active Compound Library | Alkaloids Library | Anti-Pancreatic Cancer Compound Library | Anti-Obesity Compound Library | Angiogenesis-Related Compound Library | Anti-Liver Cancer Compound Library | Anti-Colorectal Cancer Compound Library | Anti-inflammatory Traditional Chinese Medicine Active Compound Library | Plant-Sourced Natural Product Library | Human Metabolite Library | Anti-Prostate Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | Cancer Stem Cells Compound Library | Pain-Related Compound Library | Serine/Threonine Kinase Inhibitor Library | Multi-Target Compound Library | Bioactive Compound Library Max | PD98059 | Yoda 1 | SCH772984 | TBHQ | Tauroursodeoxycholate | Ulixertinib | Honokiol | β-Glycerophosphate disodium salt pentahydrate | Astragaloside IV | Piperlongumine | Temuterkib | Ravoxertinib | C16-PAF | Lidocaine | RMC-6291 | Fucoxanthin | FR 180204 | Patritumab | BIX02189 | 6-OAU | Salbutamol | trans-Zeatin | XMD8-92 | MK-8353 | Pamoic acid | ASN007 | Lysophosphatidylcholines | Urolithin B 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。